Critical Comparison: Acura Pharmaceuticals (NASDAQ:ACUR) & Flamel Technologies (AVDL)

Acura Pharmaceuticals (NASDAQ: ACUR) and Flamel Technologies (NASDAQ:AVDL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, risk and institutional ownership.

Valuation & Earnings

This table compares Acura Pharmaceuticals and Flamel Technologies’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Acura Pharmaceuticals $6.79 million N/A -$1.42 million ($0.83) -0.53
Flamel Technologies $173.99 million 2.02 $64.86 million $0.84 10.45

Flamel Technologies has higher revenue and earnings than Acura Pharmaceuticals. Acura Pharmaceuticals is trading at a lower price-to-earnings ratio than Flamel Technologies, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Acura Pharmaceuticals has a beta of 2.12, suggesting that its share price is 112% more volatile than the S&P 500. Comparatively, Flamel Technologies has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Acura Pharmaceuticals and Flamel Technologies, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Acura Pharmaceuticals 0 0 2 0 3.00
Flamel Technologies 0 0 3 0 3.00

Acura Pharmaceuticals presently has a consensus target price of $8.00, indicating a potential upside of 1,718.18%. Flamel Technologies has a consensus target price of $15.67, indicating a potential upside of 78.44%. Given Acura Pharmaceuticals’ higher possible upside, analysts plainly believe Acura Pharmaceuticals is more favorable than Flamel Technologies.

Institutional & Insider Ownership

31.2% of Acura Pharmaceuticals shares are owned by institutional investors. Comparatively, 66.8% of Flamel Technologies shares are owned by institutional investors. 7.4% of Acura Pharmaceuticals shares are owned by insiders. Comparatively, 5.1% of Flamel Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Acura Pharmaceuticals and Flamel Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Acura Pharmaceuticals 14.91% 112.19% 19.04%
Flamel Technologies 21.13% 29.84% 6.34%

Summary

Flamel Technologies beats Acura Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

Acura Pharmaceuticals Company Profile

Acura Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products. The Company’s Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is an approved and immediate-release (IR) oxycodone product in the United States. The Company’s Impede technology products include Nexafed and Nexafed Sinus Pressure + Pain. Its third deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested. The Company’s Aversion and Limitx technologies are intended to address methods associated with opioid and its Impede technology is directed at the extraction and conversion of pseudoephedrine into methamphetamine.

Flamel Technologies Company Profile

Flamel Technologies S.A. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its polymer based technology. The Company has a balanced business model consisting of an Unapproved Marketed Drugs (UMDs) business with over two approved products in the United States, Bloxiverz (neostigmine methylsulfate injection) and Vazculep (phenylephrine hydrochloride injection) that are marketed; a branded pediatric business, and a branded business, focusing on the development of products utilizing Flamel’s drug delivery platforms. The Company owns and develops drug delivery platforms, including Micropump, LiquiTime, Trigger Lock and Medusa. The Company has two direct operating subsidiaries: Flamel US Holdings, Inc. and Flamel Irish Holdings, Ltd.

Receive News & Ratings for Acura Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acura Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 

Latest News



Leave a Reply

 
© 2006-2017 Rincon Hill News.